Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Change in Account Payables: 2011-2024

Historic Change in Account Payables for Agios Pharmaceuticals (AGIO) over the last 14 years, with Dec 2024 value amounting to $6.6 million.

  • Agios Pharmaceuticals' Change in Account Payables fell 74.51% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 44.18%. This contributed to the annual value of $6.6 million for FY2024, which is 175.59% up from last year.
  • Per Agios Pharmaceuticals' latest filing, its Change in Account Payables stood at $6.6 million for FY2024, which was up 175.59% from -$8.7 million recorded in FY2023.
  • In the past 5 years, Agios Pharmaceuticals' Change in Account Payables ranged from a high of $6.6 million in FY2024 and a low of -$8.7 million during FY2023.
  • For the 3-year period, Agios Pharmaceuticals' Change in Account Payables averaged around $434,667, with its median value being $3.4 million (2022).
  • As far as peak fluctuations go, Agios Pharmaceuticals' Change in Account Payables slumped by 354.16% in 2023, and later soared by 175.59% in 2024.
  • Agios Pharmaceuticals' Change in Account Payables (Yearly) stood at $3.3 million in 2020, then slumped by 44.05% to $1.9 million in 2021, then spiked by 84.43% to $3.4 million in 2022, then plummeted by 354.16% to -$8.7 million in 2023, then spiked by 175.59% to $6.6 million in 2024.